Published in Br J Haematol on June 01, 2003
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol (2009) 1.56
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk (2012) 1.28
Drug-induced hematologic syndromes. Adv Hematol (2009) 1.11
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood (2005) 1.08
Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol (2009) 1.04
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant (2009) 1.00
Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum Gene Ther (2008) 0.96
HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Adv Hematol (2011) 0.93
Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. J Clin Pathol (2007) 0.80
Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis. Med Sci Monit (2011) 0.79
Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab. BMC Hematol (2013) 0.76
Targeting the B cell in vasculitis. Pediatr Nephrol (2008) 0.75
Use of rituximab in two unusual antibody-mediated autoimmune disorders. J R Soc Med (2005) 0.75
Continuous immunotypes describe human immune variation and predict diverse responses. Proc Natl Acad Sci U S A (2017) 0.75
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood (2008) 2.44
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood (2012) 2.21
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood (2008) 1.64
High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma (2010) 1.64
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood (2004) 1.57
The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults. Br J Haematol (2010) 1.47
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leuk Lymphoma (2011) 1.39
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood (2002) 1.39
Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma (2008) 1.38
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood (2005) 1.21
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica (2011) 1.17
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol (2010) 1.12
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol (2007) 1.10
Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biol Blood Marrow Transplant (2011) 1.02
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation (2004) 1.00
Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci (2009) 0.99
Abbreviated dose rituximab for immune-mediated hematological disorders. Am J Hematol (2008) 0.97
Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma. Leuk Lymphoma (2007) 0.95
Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases. Pathology (2002) 0.93
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood (2003) 0.93
PET positive progressive transformation of germinal centers masquerading as relapsed Hodgkin lymphoma post-autograft. Leuk Lymphoma (2006) 0.92
Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. J Antimicrob Chemother (2013) 0.91
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. Br J Haematol (2010) 0.91
Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains. Br J Haematol (2013) 0.90
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica (2011) 0.88
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma (2008) 0.88
Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother (2010) 0.86
Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leuk Lymphoma (2007) 0.85
Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. Eur J Haematol (2012) 0.82
The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant (2011) 0.81
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. Cancer (2007) 0.81
Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase. Blood Coagul Fibrinolysis (2009) 0.80
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. Am J Blood Res (2011) 0.79
The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagul Fibrinolysis (2012) 0.79
Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol (2013) 0.78
Making sense of posaconazole therapeutic drug monitoring: a practical approach. Curr Opin Infect Dis (2012) 0.78
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. Oncologist (2013) 0.78
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer (2008) 0.78
Mentoring in the management of hematological malignancies. Asia Pac J Clin Oncol (2010) 0.78
Surgical management of invasive pulmonary fungal infection in hematology patients. Ann Thorac Surg (2009) 0.78
Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leuk Lymphoma (2015) 0.78
Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk Lymphoma (2009) 0.77
Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant (2006) 0.77
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. Br J Haematol (2014) 0.77
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2008) 0.76
Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. Leuk Lymphoma (2013) 0.75
Graft versus T-cell-non-Hodgkin's lymphoma effect. J Clin Oncol (2005) 0.75
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother (2017) 0.75
Bone marrow lymphoid aggregates simulating histological features of non-Hodgkin's lymphoma in Felty's syndrome. Pathology (2005) 0.75
Prospects for stem cell transplantation in multiple sclerosis. J Clin Neurosci (2002) 0.75
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. Am J Hematol (2014) 0.75
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol (2014) 0.75
Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma. Leuk Lymphoma (2012) 0.75
Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation. Leuk Lymphoma (2012) 0.75
Daclizumab in anaplastic large cell lymphoma. Leuk Lymphoma (2006) 0.75
Novel fibrinogen mutations (Aα17Gly→Cys and Aα381Ser→Phe) occurring with a 312Thr→Ala polymorphism: allelic phase assigned by direct mass measurement. Blood Coagul Fibrinolysis (2015) 0.75
Cerebral Hodgkin lymphoma causing leptomeningeal foam cell vasculopathy with cerebral infarction. Leuk Lymphoma (2012) 0.75
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Leuk Lymphoma (2014) 0.75